Lipocine added another clinical setback as its oral postpartum depression program failed to meet its primary endpoint in individuals with postpartum depression. BioCentury’s clinical report described the result as a further setback for the company’s rapid-onset oral brexanolone candidate (LPCN 1154), following prior trial disappointment. In the same weekly update, other pivotal readouts reflected the volatility of later-stage development: Tepezza scored and Immunovant missed in thyroid eye disease. The contrast highlights the narrow margins between success and failure in immunology-adjacent and inflammatory indications. For investors and partners, the headline risk is timing—clinical failures can compress runway, while divergent Phase III readouts can shift competitive positioning quickly as companies re-route pipeline resources.